chinese奇特videos_chinese撒尿voyeur_chinese少妇and黑人_chinese少妇tube撒尿_chinese少妇voyeur_chinese帅男gay18video1069_chinese天美hdsexvideos_chinese鲜嫩videos_chinese性xxxhd_chinese真做videos_chinevideo性另类大全_chingtoilet女厕hd_chises打屁股实践国产4_c逼网站_dvd一级碟片国产a_feexxx日本_feexxx性中国hd按摩_fisting国产_free hd tube moviechese在_free hd xxxx movies video国产_free hd xxxx tubevodes日本_free videos xvideos国产_free videos性欧美_free videos性欧美另类_free 性欧美69hd_free 性欧美xxx_freeⅹ性chinese_freeblackⅹvideo_freeeⅹxx性欧美hd护士_freefromvideos性欧美

On October 27, the intelligent factory project of Anti-tumor high-end complex preparation of HOdo Group was officially started, marking the transformation and upgrading of HOdo's big health industry and means that the intelligent manufacturing of HOdo Group has reached a new stage.

Haijiang Zhou said in his speech that in the face of the current complex situation, HOdo Group's response is to actively practice the new development concept, accelerate the evolution & upgrading of the enterprise, and continue to promote the construction of intelligent, green, online, high-end, international and standardized "Six." This project is an important embodiment of the Group's acceleration of intelligent and high-end development. It is reported that the project is a key project to enhance the international competitiveness of the enterprise, with a total investment of 520 million yuan and an annual output of 20 million bottles of anti-tumour injections and 100 million tablets of anti-tumour solid preparations, realizing an output value of more than 1.5 billion yuan and an annual profit of 300 million yuan. The project will construct three production lines for anti-tumour preparations, including a non-final sterilization production line for anti-tumour injections, a final sterilization production line for anti-tumour injections, and an anti-tumour solid preparation production line, which all in accordance with Chinese GMP, FDA, EU and other international first-class standards, all the use of international first-class intelligent equipment and facilities, combined with the CONCEPT of QbD design and construction of the top factory facilities, CIP/SIP(VHP sterilization) and fully closed (Isolator) sterile filling line. The advanced fully sealed RTP system transfers sterile materials, and the computerized system covers the entire isolator filling line, sterile transfer and lyophilization. The whole production process is automatic and intelligent. The project is expected to be produced in the first half of 2023, significantly improving the Group's pharmaceutical production capacity, technology level, and product market competitiveness.